116 related articles for article (PubMed ID: 20005102)
41. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
42. Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta.
Ma Y; Wang M; Li N; Wu R; Wang X
Toxicol Lett; 2009 Jun; 187(3):194-200. PubMed ID: 19429264
[TBL] [Abstract][Full Text] [Related]
43. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
[TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
45. Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.
Lynch SM; DeVicente J; Hermann JC; Jaime-Figueroa S; Jin S; Kuglstatter A; Li H; Lovey A; Menke J; Niu L; Patel V; Roy D; Soth M; Steiner S; Tivitmahaisoon P; Vu MD; Yee C
Bioorg Med Chem Lett; 2013 May; 23(9):2793-800. PubMed ID: 23540648
[TBL] [Abstract][Full Text] [Related]
46. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
Estrada AC; Syrovets T; Pitterle K; Lunov O; Büchele B; Schimana-Pfeifer J; Schmidt T; Morad SA; Simmet T
Mol Pharmacol; 2010 Mar; 77(3):378-87. PubMed ID: 20018812
[TBL] [Abstract][Full Text] [Related]
47. Rapid assembly of diverse and potent allosteric Akt inhibitors.
Wu Z; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Kohl NE; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2008 Mar; 18(6):2211-4. PubMed ID: 18296048
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors.
Stevens KL; Reno MJ; Alberti JB; Price DJ; Kane-Carson LS; Knick VB; Shewchuk LM; Hassell AM; Veal JM; Davis ST; Griffin RJ; Peel MR
Bioorg Med Chem Lett; 2008 Nov; 18(21):5758-62. PubMed ID: 18835709
[TBL] [Abstract][Full Text] [Related]
49. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
[TBL] [Abstract][Full Text] [Related]
51. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
[TBL] [Abstract][Full Text] [Related]
52. Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.
Lesuisse D; Tiraboschi G; Krick A; Abecassis PY; Dutruc-Rosset G; Babin D; Halley F; Châtreau F; Lachaud S; Chevalier A; Quarteronet D; Burgevin MC; Amara C; Bertrand P; Rooney T
Bioorg Med Chem Lett; 2010 Apr; 20(7):2344-9. PubMed ID: 20189807
[TBL] [Abstract][Full Text] [Related]
53. Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells.
Dozza B; Smith MA; Perry G; Tabaton M; Strocchi P
J Neurochem; 2004 Jun; 89(5):1224-32. PubMed ID: 15147515
[TBL] [Abstract][Full Text] [Related]
54. Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.
Ye L; Ou X; Tian Y; Yu B; Luo Y; Feng B; Lin H; Zhang J; Wu S
Eur J Med Chem; 2013 Jul; 65():112-8. PubMed ID: 23702473
[TBL] [Abstract][Full Text] [Related]
55. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.
Kim N; Kim CH; Ahn DW; Lee KS; Cho SJ; Park JH; Lee MK; Kim JS; Jung HC; Song IS
J Gastroenterol Hepatol; 2009 Mar; 24(3):480-7. PubMed ID: 18823436
[TBL] [Abstract][Full Text] [Related]
56. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kawaguchi K; Kaizawa H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Parker P; Workman P; Waterfield MD
Bioorg Med Chem; 2007 Sep; 15(17):5837-44. PubMed ID: 17601739
[TBL] [Abstract][Full Text] [Related]
58. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
Currie KS; Kropf JE; Lee T; Blomgren P; Xu J; Zhao Z; Gallion S; Whitney JA; Maclin D; Lansdon EB; Maciejewski P; Rossi AM; Rong H; Macaluso J; Barbosa J; Di Paolo JA; Mitchell SA
J Med Chem; 2014 May; 57(9):3856-73. PubMed ID: 24779514
[TBL] [Abstract][Full Text] [Related]
59. Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation.
De Falco F; Sabatini R; Falzetti F; Di Ianni M; Sportoletti P; Baldoni S; Del Papa B; Screpanti I; Marconi P; Rosati E
Leukemia; 2015 Apr; 29(4):994-8. PubMed ID: 25425197
[No Abstract] [Full Text] [Related]
60. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.
Terao Y; Suzuki H; Yoshikawa M; Yashiro H; Takekawa S; Fujitani Y; Okada K; Inoue Y; Yamamoto Y; Nakagawa H; Yao S; Kawamoto T; Uchikawa O
Bioorg Med Chem Lett; 2012 Dec; 22(24):7326-9. PubMed ID: 23147077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
